Regulatory & Reimbursement
FDA Output, February 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in February 2026. Updated February 23.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Investors & Dealmaking
The Digest: February 2026
In this month's news, Medtronic gets clearance for fast-acting insulin pump, VB Spine to buy SpineHawk, strategic profit forecasts vary, and more.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Regulatory & Reimbursement
Pathways' Pick of the Week: MDUFA VI Talks: Sticking Points and Progress
MDUFA VI talks between FDA and industry advance, with some snags. Excerpted from Pathways’ Picks Febraury 11: User Fee Sticking Points, AdvaMed Hire, China Clinical Trial Policy.